GLP-1 Medications Like Ozempic and Wegovy Show Promise in Treating Addiction Risk and Symptoms
Recent clinical evidence indicates that glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy), originally developed for type 2 diabetes and obesity, are showing promise in ... Read More